The Infectious Diseases Society of America supports the CDC Advisory Committee on Immunization Practice’s unanimous recommendation to allow “mix-and-match”—or heterologous—COVID-19 booster shots for at-risk populations.
IDSA and HIVMA applaud the bipartisan introduction of the Bolstering Infectious Outbreaks (BIO) Preparedness Workforce Act by Reps. Lori Trahan (D-MA) and David McKinley (R-WV), H.R. 5602, and its inclusion in an Oct. 26 Energy and Commerce Health Subcommittee hearing.
On October 15, 2021, IDSA released revised remarks and a new evidence profile for the use of baricitinib for critically ill patients requiring invasive mechanical ventilation; this update has been endorsed by SIDP.
In legal rulings issued on Sept. 1 and Sept. 20, a federal judge in Texas dismissed all claims a group of Lyme disease patients had brought against the Infectious Diseases Society of America.
Infections caused by bacteria resistant to multiple antibiotics led to $1.9 billion in health care costs, more than 400,000 days in the hospital and more than 10,000 deaths among older adults across the U.S. in 2017, according to a new study published today in Clinical Infectious Diseases.